8-KRegulation FDExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Regulation FD Disclosure (Dec 16, 2016)

Filed December 16, 2016For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) announced a significant change in its Board of Directors' leadership structure, effective January 1, 2017. The company has decided to combine the roles of Chairman of the Board and President and Chief Executive Officer, appointing current CEO Stephen H. Rusckowski to both positions. This move aims to streamline board administration, facilitate effective execution of the company's strategic vision, and enhance overall operational efficiency under a unified leadership. To maintain independent oversight and robust director judgment, the Board has also appointed Dr. Daniel C. Stanzione as the Lead Independent Director. This role comes with significantly enhanced authority, including involvement in board agenda setting, presiding over executive sessions of non-management directors, evaluating the CEO, and serving as a primary contact for stockholder communications with the independent directors. This dual approach seeks to balance executive leadership with strong independent governance.

Key Highlights

  • 1Effective January 1, 2017, CEO Stephen H. Rusckowski will assume the additional role of Chairman of the Board, combining executive and board leadership.
  • 2Dr. Daniel C. Stanzione has been designated as the Lead Independent Director, enhancing independent oversight.
  • 3The Board believes combining the CEO and Chairman roles will improve board administration and strategic execution.
  • 4The Lead Independent Director role has been enhanced with expanded responsibilities and authority to ensure independent judgment.
  • 5Key responsibilities of the Lead Independent Director include presiding over non-management director sessions, evaluating the CEO, and serving as a liaison for stockholder communications with independent directors.
  • 6The company retains flexibility to adjust its leadership structure if deemed necessary by the Board.

Frequently Asked Questions

The primary change is the consolidation of the Chairman of the Board and President and CEO roles under Stephen H. Rusckowski, effective January 1, 2017. This means the CEO will also serve as the Chairman of the Board.

To counterbalance the combined executive leadership, the Board has appointed a Lead Independent Director, Dr. Daniel C. Stanzione. This role has been significantly strengthened with enhanced authority and responsibilities to ensure independent perspectives and robust governance.

The Lead Independent Director will participate in setting board agendas, preside over executive sessions of non-management directors, lead the CEO's performance evaluation, and act as the main contact for stockholder communications directed at the independent directors.

The Board concluded that combining the roles would enhance board administration, facilitate the effective conduct of its duties, and drive more efficient execution of the company's strategic plans and vision.